Biorthex Anticipating Fourth-Quarter Roll-Out Of SpineCor Scoliosis Brace
This article was originally published in The Gray Sheet
Executive Summary
Biorthex is planning a fourth-quarter U.S. launch of its SpineCor scoliosis brace, pending 510(k) clearance by FDA. Priced at approximately $1,000, the device will be positioned as an alternative and less restrictive treatment for early idiopathic scoliosis.